Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2016

01.02.2016 | Preclinical study

Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas

verfasst von: Mayu Takagi, Yasuhiro Miki, Minoru Miyashita, Shuko Hata, Tomomi Yoda, Hisashi Hirakawa, Yasuaki Sagara, Yoshiaki Rai, Yasuyo Ohi, Kentaro Tamaki, Takanori Ishida, Takashi Suzuki, Noriaki Ouchi, Hironobu Sasano

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The great majority of invasive lobular carcinoma (ILC) is estrogen-dependent luminal A type carcinoma but the details of estrogen actions and its intratumoral metabolism have not been well studied compared to invasive ductal carcinoma (IDC). We first immunolocalized estrogen-related enzymes including estrogen sulfotransferase (EST), estrogen sulfatase (STS), 17β-hydroxysteroid dehydrogenase (HSD) 1/2, and aromatase. We then evaluated the tissue concentrations of estrogens in ILC and IDC and subsequently estrogen-responsive gene profiles in these tumors in order to explore the possible differences and/or similarity of intratumoral estrogen environment of these two breast cancer subtypes. The status of STS and 17βHSD1 was significantly lower in ILCs than IDCs (p = 0.022 and p < 0.0001), but that of EST and 17βHSD2 vice versa (p < 0.0001 and p = 0.0106). In ILCs, tissue concentrations of estrone and estradiol were lower than those in IDCs (p = 0.0709 and 0.069). In addition, the great majority of estrogen response genes tended to be lower in ILCs. Among those genes above, FOXP1 was significantly higher in ILCs than in IDCs (p = 0.002). FOXP1 expression was reported to be significantly higher in relapse-free IDC patients treated with tamoxifen. Therefore, tamoxifen may be considered an option of endocrine therapy for luminal A type ILC patients. This is the first study to demonstrate the detailed and comprehensive status of intratumoral production and metabolism of estrogens and the status of estrogen response genes in luminal A-like ILC with comparison to those in luminal A-like IDCs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Fisher ER, Gregorio RM, Fisher B et al (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36(1):1–85CrossRefPubMed Fisher ER, Gregorio RM, Fisher B et al (1975) The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36(1):1–85CrossRefPubMed
2.
Zurück zum Zitat Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156CrossRefPubMedPubMedCentral Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Sastre-Garau X, Jouve M, Asselain B et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77(1):113–120CrossRefPubMed Sastre-Garau X, Jouve M, Asselain B et al (1996) Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 77(1):113–120CrossRefPubMed
4.
5.
Zurück zum Zitat Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014CrossRefPubMed Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26(18):3006–3014CrossRefPubMed
6.
Zurück zum Zitat Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG (2002) Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 87(10):1105–1111CrossRefPubMedPubMedCentral Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG (2002) Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer 87(10):1105–1111CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Cocquyt VF, Blondeel PN, Depypere HT et al (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29(4):361–367CrossRefPubMed Cocquyt VF, Blondeel PN, Depypere HT et al (2003) Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 29(4):361–367CrossRefPubMed
8.
Zurück zum Zitat Mersin H, Yildirim E, Gulben K, Berberoglu U (2003) Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 29(4):390–395CrossRefPubMed Mersin H, Yildirim E, Gulben K, Berberoglu U (2003) Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 29(4):390–395CrossRefPubMed
9.
Zurück zum Zitat Suzuki T, Miki Y, Moriya T et al (2007) In situ production of sex steroids in human breast carcinoma. Med Mol Morphol 40(3):121–127CrossRefPubMed Suzuki T, Miki Y, Moriya T et al (2007) In situ production of sex steroids in human breast carcinoma. Med Mol Morphol 40(3):121–127CrossRefPubMed
10.
Zurück zum Zitat Suzuki T, Nakata T, Miki Y et al (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63(11):2762–2770PubMed Suzuki T, Nakata T, Miki Y et al (2003) Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res 63(11):2762–2770PubMed
11.
Zurück zum Zitat Pasqualini JR, Chetrite GS (1999) Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol 69(1–6):287–292CrossRefPubMed Pasqualini JR, Chetrite GS (1999) Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential clinical applications. J Steroid Biochem Mol Biol 69(1–6):287–292CrossRefPubMed
12.
Zurück zum Zitat Suzuki T, Miki Y, Nakamura Y et al (2005) Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 12(4):701–720CrossRefPubMed Suzuki T, Miki Y, Nakamura Y et al (2005) Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 12(4):701–720CrossRefPubMed
13.
Zurück zum Zitat Yoda T, McNamara KM, Miki Y et al (2014) Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Sci 105(11):1503–1509CrossRefPubMedPubMedCentral Yoda T, McNamara KM, Miki Y et al (2014) Intratumoral androgen metabolism and actions in invasive lobular carcinoma of the breast. Cancer Sci 105(11):1503–1509CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Sasano H, Suzuki T, Nakata T, Moriya T (2006) New development in intracrinology of breast carcinoma. Breast Cancer 13(2):129–136CrossRefPubMed Sasano H, Suzuki T, Nakata T, Moriya T (2006) New development in intracrinology of breast carcinoma. Breast Cancer 13(2):129–136CrossRefPubMed
15.
Zurück zum Zitat Miksits M, Wlcek K, Svoboda M et al (2010) Expression of sulfotransferases and sulfatases in human breast cancer: impact on resveratrol metabolism. Cancer Lett 289(2):237–245CrossRefPubMed Miksits M, Wlcek K, Svoboda M et al (2010) Expression of sulfotransferases and sulfatases in human breast cancer: impact on resveratrol metabolism. Cancer Lett 289(2):237–245CrossRefPubMed
16.
Zurück zum Zitat Ahmed M, Esposito E (2015) Report from the 37th San Antonio Breast Cancer Symposium, 9–13th December 2014, Texas, USA. Ecancermedicalscience 9:508CrossRefPubMedPubMedCentral Ahmed M, Esposito E (2015) Report from the 37th San Antonio Breast Cancer Symposium, 9–13th December 2014, Texas, USA. Ecancermedicalscience 9:508CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Metzger OG-HA, Mallon E, Viale G et al (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol 33(25):2772–2779CrossRef Metzger OG-HA, Mallon E, Viale G et al (2015) Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol 33(25):2772–2779CrossRef
18.
Zurück zum Zitat Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519CrossRefPubMed Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163(2):506–519CrossRefPubMed
19.
Zurück zum Zitat Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206–2223CrossRefPubMedPubMedCentral Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24(9):2206–2223CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410CrossRefPubMed Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410CrossRefPubMed
21.
Zurück zum Zitat Nakagawa S, Miki Y, Miyashita M et al (2016) Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res Treat 155(1):65–75CrossRefPubMed Nakagawa S, Miki Y, Miyashita M et al (2016) Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Res Treat 155(1):65–75CrossRefPubMed
22.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795CrossRefPubMedPubMedCentral Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118–145CrossRefPubMed
24.
Zurück zum Zitat Miki Y, Suzuki T, Tazawa C et al (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67(8):3945–3954CrossRefPubMed Miki Y, Suzuki T, Tazawa C et al (2007) Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 67(8):3945–3954CrossRefPubMed
25.
Zurück zum Zitat Sasano H, Miki Y, Nagasaki S, Suzuki T (2009) In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int 59(11):777–789CrossRefPubMed Sasano H, Miki Y, Nagasaki S, Suzuki T (2009) In situ estrogen production and its regulation in human breast carcinoma: from endocrinology to intracrinology. Pathol Int 59(11):777–789CrossRefPubMed
26.
Zurück zum Zitat Shibuya R, Suzuki T, Miki Y et al (2008) Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 15(1):113–124CrossRefPubMed Shibuya R, Suzuki T, Miki Y et al (2008) Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer 15(1):113–124CrossRefPubMed
27.
Zurück zum Zitat Ijichi N, Shigekawa T, Ikeda K et al (2012) Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer 3(4):147–159CrossRefPubMed Ijichi N, Shigekawa T, Ikeda K et al (2012) Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients. Horm Cancer 3(4):147–159CrossRefPubMed
28.
Zurück zum Zitat Shigekawa T, Ijichi N, Ikeda K et al (2011) FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer 2(5):286–297CrossRefPubMed Shigekawa T, Ijichi N, Ikeda K et al (2011) FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer 2(5):286–297CrossRefPubMed
29.
Zurück zum Zitat Masuda M, Miki Y, Hata S et al (2012) An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J Transl Med 10(Suppl 1):S2CrossRefPubMedPubMedCentral Masuda M, Miki Y, Hata S et al (2012) An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. J Transl Med 10(Suppl 1):S2CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Picard N, Caron V, Bilodeau S et al (2012) Identification of estrogen receptor β as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3β. Mol Cell Biol 2(14):2709–2721CrossRef Picard N, Caron V, Bilodeau S et al (2012) Identification of estrogen receptor β as a SUMO-1 target reveals a novel phosphorylated sumoylation motif and regulation by glycogen synthase kinase 3β. Mol Cell Biol 2(14):2709–2721CrossRef
31.
Zurück zum Zitat Urano T, Saito T, Tsukui T et al (2002) Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417(6891):871–875CrossRefPubMed Urano T, Saito T, Tsukui T et al (2002) Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417(6891):871–875CrossRefPubMed
32.
Zurück zum Zitat Mo R, Zhu YT, Tony YJ, Zhang Z, Rao SM (2007) GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem Biophys Res Commun. 353(1):189–194CrossRefPubMedPubMedCentral Mo R, Zhu YT, Tony YJ, Zhang Z, Rao SM (2007) GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochem Biophys Res Commun. 353(1):189–194CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Seksenyan A, Kadavallore A, Walts AE et al (2015) TOX3 is expressed in mammary ER+ epithelial cells and regulates ER target genes in luminal breast cancer. BMC Cancer 15(1):22CrossRefPubMedPubMedCentral Seksenyan A, Kadavallore A, Walts AE et al (2015) TOX3 is expressed in mammary ER+ epithelial cells and regulates ER target genes in luminal breast cancer. BMC Cancer 15(1):22CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Suzuki T, Urano T, Tsukui T et al (2005) Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 11(17):6148–6154CrossRefPubMed Suzuki T, Urano T, Tsukui T et al (2005) Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res 11(17):6148–6154CrossRefPubMed
35.
Zurück zum Zitat McCormack O, Chung WY, Fitzpatrick P et al (2008) Growth arrest-specific gene 6 expression in human breast cancer. Br J Cancer 98(6):1141–1146CrossRef McCormack O, Chung WY, Fitzpatrick P et al (2008) Growth arrest-specific gene 6 expression in human breast cancer. Br J Cancer 98(6):1141–1146CrossRef
36.
Zurück zum Zitat Nagasaki S, Suzuki T, Miki Y et al (2009) 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 69(4):1392–1399CrossRefPubMed Nagasaki S, Suzuki T, Miki Y et al (2009) 17Beta-hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 69(4):1392–1399CrossRefPubMed
37.
Zurück zum Zitat Takagi K, Miki Y, Nagasaki S (2010) Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer 17(2):415–430CrossRefPubMed Takagi K, Miki Y, Nagasaki S (2010) Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocr Relat Cancer 17(2):415–430CrossRefPubMed
38.
Zurück zum Zitat Bourdeau V, Deschênes J, Métivier R et al (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18(6):1411–1427CrossRefPubMed Bourdeau V, Deschênes J, Métivier R et al (2004) Genome-wide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18(6):1411–1427CrossRefPubMed
39.
Zurück zum Zitat Turashvili G, Bouchal J, Baumforth K et al (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55CrossRefPubMedPubMedCentral Turashvili G, Bouchal J, Baumforth K et al (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7:55CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Lin X, Li J, Yin G et al (2013) Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res 15(6):R119CrossRefPubMedPubMedCentral Lin X, Li J, Yin G et al (2013) Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. Breast Cancer Res 15(6):R119CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Jung SY, Jeong J, Shin SH et al (2010) The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer 10:664CrossRefPubMedPubMedCentral Jung SY, Jeong J, Shin SH et al (2010) The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer 10:664CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156CrossRefPubMedPubMedCentral Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6(3):R149–R156CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Mersin H, Yildirim E, Gülben K, Berberoğlu U (2003) Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 29(4):390–395CrossRefPubMed Mersin H, Yildirim E, Gülben K, Berberoğlu U (2003) Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 29(4):390–395CrossRefPubMed
44.
Zurück zum Zitat Berx G, Cleton-Jansen AM, Strumane K et al (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13(9):1919–1925PubMed Berx G, Cleton-Jansen AM, Strumane K et al (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13(9):1919–1925PubMed
45.
Zurück zum Zitat Rakha EA, Patel A, Powe DG et al (2010) Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 34(10):1472–1479CrossRefPubMed Rakha EA, Patel A, Powe DG et al (2010) Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 34(10):1472–1479CrossRefPubMed
46.
Zurück zum Zitat Fernández B, Paish EC, Green AR et al (2011) Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. J Clin Pathol 64(11):995–1000CrossRefPubMed Fernández B, Paish EC, Green AR et al (2011) Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. J Clin Pathol 64(11):995–1000CrossRefPubMed
47.
Zurück zum Zitat Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253–261CrossRefPubMed Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253–261CrossRefPubMed
Metadaten
Titel
Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas
verfasst von
Mayu Takagi
Yasuhiro Miki
Minoru Miyashita
Shuko Hata
Tomomi Yoda
Hisashi Hirakawa
Yasuaki Sagara
Yoshiaki Rai
Yasuyo Ohi
Kentaro Tamaki
Takanori Ishida
Takashi Suzuki
Noriaki Ouchi
Hironobu Sasano
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2016
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3739-6

Weitere Artikel der Ausgabe 1/2016

Breast Cancer Research and Treatment 1/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.